<?xml version="1.0" encoding="UTF-8"?>
<search_results count="1046">
  <query>SEARCH[STUDY] ( Crohn's Disease [STUDY:ALL-FIELDS] )</query>
  <clinical_study>
    <order>401</order>
    <score>0.89606</score>
    <nct_id>NCT02630966</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02630966</url>
    <title>Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab; Drug: Placebo</intervention_summary>
    <last_changed>July 7, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>402</order>
    <score>0.89595</score>
    <nct_id>NCT00055367</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00055367</url>
    <title>Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: natalizumab</intervention_summary>
    <last_changed>June 14, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>403</order>
    <score>0.89582</score>
    <nct_id>NCT00234741</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00234741</url>
    <title>Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: STA-5326 mesylate</intervention_summary>
    <last_changed>December 3, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>404</order>
    <score>0.89582</score>
    <nct_id>NCT00055523</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00055523</url>
    <title>A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Adalimumab (D2E7)</intervention_summary>
    <last_changed>August 11, 2006</last_changed>
  </clinical_study>
  <clinical_study>
    <order>405</order>
    <score>0.89567</score>
    <nct_id>NCT00374374</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00374374</url>
    <title>Treatment With Lactobacillus Rhamnosus and Lactobacillus Acidophilus for Patients With Active Colonic Crohn’s Disease.</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Behavioral: Administration of probiotic</intervention_summary>
    <last_changed>September 7, 2006</last_changed>
  </clinical_study>
  <clinical_study>
    <order>406</order>
    <score>0.89557</score>
    <nct_id>NCT00055536</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00055536</url>
    <title>Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: natalizumab</intervention_summary>
    <last_changed>June 14, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>407</order>
    <score>0.89549</score>
    <nct_id>NCT01277289</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01277289</url>
    <title>Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Dexamethasone</intervention_summary>
    <last_changed>September 18, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>408</order>
    <score>0.89543</score>
    <nct_id>NCT00206596</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00206596</url>
    <title>Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Sargramostim (Leukine); Drug: Placebo</intervention_summary>
    <last_changed>December 2, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>409</order>
    <score>0.89537</score>
    <nct_id>NCT00367705</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00367705</url>
    <title>VSL#3 Treatment in Children With Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Dietary Supplement: VSL#3®; Dietary Supplement: Placebo</intervention_summary>
    <last_changed>August 16, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>410</order>
    <score>0.89519</score>
    <nct_id>NCT00295165</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00295165</url>
    <title>Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Sargramostim (Leukine); Drug: Placebo</intervention_summary>
    <last_changed>December 2, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>411</order>
    <score>0.89497</score>
    <nct_id>NCT00195715</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00195715</url>
    <title>Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Adalimumab</intervention_summary>
    <last_changed>July 8, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>412</order>
    <score>0.89475</score>
    <nct_id>NCT01562951</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01562951</url>
    <title>Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease; Mucosal Inflammation</condition_summary>
    <intervention_summary>Drug: ADALIMUMAB; Drug: Placebo</intervention_summary>
    <last_changed>May 3, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>413</order>
    <score>0.89475</score>
    <nct_id>NCT03105102</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03105102</url>
    <title>A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: risankizumab SC; Drug: placebo for risankizumab SC; Drug: risankizumab IV; Drug: placebo for risankizumab IV</intervention_summary>
    <last_changed>April 4, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>414</order>
    <score>0.89461</score>
    <nct_id>NCT00989573</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00989573</url>
    <title>A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Placebo; Drug: OPC-6535; Drug: OPC-6535</intervention_summary>
    <last_changed>February 19, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>415</order>
    <score>0.89454</score>
    <nct_id>NCT00077779</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00077779</url>
    <title>Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Adalimumab</intervention_summary>
    <last_changed>September 23, 2007</last_changed>
  </clinical_study>
  <clinical_study>
    <order>416</order>
    <score>0.89451</score>
    <nct_id>NCT00280956</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00280956</url>
    <title>Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: natalizumab</intervention_summary>
    <last_changed>June 14, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>417</order>
    <score>0.89441</score>
    <nct_id>NCT02834754</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02834754</url>
    <title>A Randomized, Double-blind, Placebo Controlled Study of Vedolizumab for the Prevention of Post-operative Crohn's Disease Recurrence</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab; Drug: placebo</intervention_summary>
    <last_changed>July 14, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>418</order>
    <score>0.89438</score>
    <nct_id>NCT01466374</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01466374</url>
    <title>Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Placebo; Drug: Placebo; Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody)</intervention_summary>
    <last_changed>September 23, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>419</order>
    <score>0.89423</score>
    <nct_id>NCT00446433</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00446433</url>
    <title>A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: CC-5013</intervention_summary>
    <last_changed>November 30, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>420</order>
    <score>0.89414</score>
    <nct_id>NCT03234907</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03234907</url>
    <title>Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab IV; Drug: Placebo</intervention_summary>
    <last_changed>July 26, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>421</order>
    <score>0.8941</score>
    <nct_id>NCT02403323</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02403323</url>
    <title>Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: etrolizumab</intervention_summary>
    <last_changed>March 15, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>422</order>
    <score>0.89376</score>
    <nct_id>NCT01053559</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01053559</url>
    <title>Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: certolizumab pegol</intervention_summary>
    <last_changed>April 23, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>423</order>
    <score>0.89371</score>
    <nct_id>NCT02641171</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02641171</url>
    <title>Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Lack of intervention</intervention_summary>
    <last_changed>December 28, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>424</order>
    <score>0.89366</score>
    <nct_id>NCT00586599</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00586599</url>
    <title>Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis</condition_summary>
    <intervention_summary>Other: measurement of inflammatory markers</intervention_summary>
    <last_changed>April 1, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>425</order>
    <score>0.89349</score>
    <nct_id>NCT02499783</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02499783</url>
    <title>Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Adalimumab; Other: Placebo</intervention_summary>
    <last_changed>April 21, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>426</order>
    <score>0.89348</score>
    <nct_id>NCT02611817</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02611817</url>
    <title>Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab SC 108; Drug: Placebo SC; Drug: Vedolizumab IV 300 mg</intervention_summary>
    <last_changed>June 22, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>427</order>
    <score>0.8933</score>
    <nct_id>NCT00338650</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00338650</url>
    <title>Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: adalimumab</intervention_summary>
    <last_changed>November 28, 2007</last_changed>
  </clinical_study>
  <clinical_study>
    <order>428</order>
    <score>0.89321</score>
    <nct_id>NCT00427921</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00427921</url>
    <title>Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: adalimumab</intervention_summary>
    <last_changed>November 12, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>429</order>
    <score>0.89317</score>
    <nct_id>NCT03185624</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03185624</url>
    <title>Effectiveness of Rifaximin on Preventing Postoperative Recurrence in Crohn's Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Rifaximin</intervention_summary>
    <last_changed>July 18, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>430</order>
    <score>0.89314</score>
    <nct_id>NCT03058679</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03058679</url>
    <title>Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Other: Diet</intervention_summary>
    <last_changed>July 10, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>431</order>
    <score>0.89306</score>
    <nct_id>NCT02445690</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02445690</url>
    <title>Thrombin Generation in Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn Disease; Blood Clot; Thrombosis</condition_summary>
    <last_changed>May 11, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>432</order>
    <score>0.89303</score>
    <nct_id>NCT02882841</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02882841</url>
    <title>MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Biopsies, stool and blood collection</intervention_summary>
    <last_changed>March 20, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>433</order>
    <score>0.89285</score>
    <nct_id>NCT02321280</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02321280</url>
    <title>The Efficacy of Denosumab in Active Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Denosumab</intervention_summary>
    <last_changed>May 4, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>434</order>
    <score>0.89265</score>
    <nct_id>NCT00105300</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00105300</url>
    <title>Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Adalimumab</intervention_summary>
    <last_changed>August 13, 2006</last_changed>
  </clinical_study>
  <clinical_study>
    <order>435</order>
    <score>0.89258</score>
    <nct_id>NCT00615199</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00615199</url>
    <title>A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo</intervention_summary>
    <last_changed>January 18, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>436</order>
    <score>0.89246</score>
    <nct_id>NCT00737932</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00737932</url>
    <title>Laquinimod Phase IIa Study in Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Laquinimod; Other: placebo</intervention_summary>
    <last_changed>March 19, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>437</order>
    <score>0.89234</score>
    <nct_id>NCT00278577</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00278577</url>
    <title>Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>CROHN'S DISEASE</condition_summary>
    <intervention_summary>Biological: Immune Ablation and Hematopoietic Stem Cell Support</intervention_summary>
    <last_changed>February 4, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>438</order>
    <score>0.89187</score>
    <nct_id>NCT01378390</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01378390</url>
    <title>Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Complex Perianal Fistula; Crohn Disease</condition_summary>
    <intervention_summary>Drug: Expanded autologous adipose-derived adult stem cells (eASCs); Drug: Placebo</intervention_summary>
    <last_changed>June 21, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>439</order>
    <score>0.89171</score>
    <nct_id>NCT03185611</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03185611</url>
    <title>Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Rifaximin; Drug: Azathioprine</intervention_summary>
    <last_changed>June 12, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>440</order>
    <score>0.8916</score>
    <nct_id>NCT00771667</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00771667</url>
    <title>A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Placebo (IP); Drug: Ustekinumab 1mg/kg (IP); Drug: Ustekinumab 3 mg/kg (IP); Drug: Ustekinumab 6 mg/kg (IP); Drug: Placebo IV - Responder - Placebo SC (MP); Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP); Drug: Ustekinumab IV - Responder - Placebo SC (MP); Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP); Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP); Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)</intervention_summary>
    <last_changed>March 26, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>441</order>
    <score>0.89157</score>
    <nct_id>NCT00160524</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00160524</url>
    <title>A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Certolizumab Pegol (CDP870)</intervention_summary>
    <last_changed>August 2, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>442</order>
    <score>0.89153</score>
    <nct_id>NCT02031276</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02031276</url>
    <title>Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: ABBV-066; Drug: ABBV-066; Drug: Placebo</intervention_summary>
    <last_changed>November 30, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>443</order>
    <score>0.89125</score>
    <nct_id>NCT02108938</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02108938</url>
    <title>Brain-Gut Interactions in Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>October 31, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>444</order>
    <score>0.89095</score>
    <nct_id>NCT00048113</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00048113</url>
    <title>Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Alicaforsen</intervention_summary>
    <last_changed>October 15, 2007</last_changed>
  </clinical_study>
  <clinical_study>
    <order>445</order>
    <score>0.89085</score>
    <nct_id>NCT01817426</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01817426</url>
    <title>Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Infliximab; Other: Placebo</intervention_summary>
    <last_changed>October 31, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>446</order>
    <score>0.89079</score>
    <nct_id>NCT00074542</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00074542</url>
    <title>An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Epanova™ (Omega-3 Free Fatty Acids)</intervention_summary>
    <last_changed>February 20, 2007</last_changed>
  </clinical_study>
  <clinical_study>
    <order>447</order>
    <score>0.89072</score>
    <nct_id>NCT00819663</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00819663</url>
    <title>Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>August 17, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>448</order>
    <score>0.89051</score>
    <nct_id>NCT02793778</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02793778</url>
    <title>Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: CROWN; Drug: CROWN Placebo</intervention_summary>
    <last_changed>April 26, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>449</order>
    <score>0.89044</score>
    <nct_id>NCT00048295</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00048295</url>
    <title>Alicaforsen (ISIS 2302) in Patients With Active Crohn’s Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Alicaforsen</intervention_summary>
    <last_changed>June 23, 2005</last_changed>
  </clinical_study>
  <clinical_study>
    <order>450</order>
    <score>0.89035</score>
    <nct_id>NCT01593462</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01593462</url>
    <title>Comparative Effectiveness of MR Enterography</title>
    <status open="N">Completed</status>
    <condition_summary>Crohns Disease</condition_summary>
    <intervention_summary>Procedure: MRE (magnetic resonance enterography); Procedure: The Ultrasound scan, (UEI) Ultrasound Elastography Imaging with ARFI (acoustic radiation force impulse); Behavioral: Study Questionnaires</intervention_summary>
    <last_changed>January 20, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>451</order>
    <score>0.89001</score>
    <nct_id>NCT02332356</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02332356</url>
    <title>Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: azathioprine or adalimumab and infliximab</intervention_summary>
    <last_changed>January 4, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>452</order>
    <score>0.88954</score>
    <nct_id>NCT00160706</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00160706</url>
    <title>A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Certolizumab Pegol (CDP870)</intervention_summary>
    <last_changed>May 16, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>453</order>
    <score>0.88932</score>
    <nct_id>NCT02772965</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02772965</url>
    <title>Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Pediatric Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Methotrexate; Other: Sugar pill (placebo)</intervention_summary>
    <last_changed>July 25, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>454</order>
    <score>0.88929</score>
    <nct_id>NCT01696838</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01696838</url>
    <title>Efficacy of Acupuncture and Moxibustion Treatment in Patients With Quiescent Crohn's Disease:Evaluation With fMRI</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; CAM</condition_summary>
    <intervention_summary>Other: electroacupuncture; Other: moxibustion</intervention_summary>
    <last_changed>September 2, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>455</order>
    <score>0.88903</score>
    <nct_id>NCT00287170</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00287170</url>
    <title>Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Delayed Release 6MP or Calcitriol vs. Purinethol</intervention_summary>
    <last_changed>July 3, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>456</order>
    <score>0.88891</score>
    <nct_id>NCT00583232</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00583232</url>
    <title>Protein and Energy Metabolism in Pediatric Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Protein Metabolism; Energy Metabolism</condition_summary>
    <intervention_summary>Drug: Stable isotope infusions</intervention_summary>
    <last_changed>March 14, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>457</order>
    <score>0.88889</score>
    <nct_id>NCT02060318</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02060318</url>
    <title>Regulatory T-cells and Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Infliximab</intervention_summary>
    <last_changed>June 20, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>458</order>
    <score>0.88883</score>
    <nct_id>NCT01019460</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01019460</url>
    <title>A Comparative Study of Capsule Endoscopy, Magnetic Resonance Imaging and Computer Tomography Scanning of the Small Bowel in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Procedure: Magnetic resonance imaging, computed tomography scanning and capsule endoscopy</intervention_summary>
    <last_changed>September 20, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>459</order>
    <score>0.88881</score>
    <nct_id>NCT02839317</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02839317</url>
    <title>COmparison of MicroBiota AccordIng to Age in Crohn's Disease (COMeBACk)</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Biological</intervention_summary>
    <last_changed>January 17, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>460</order>
    <score>0.88755</score>
    <nct_id>NCT02997059</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02997059</url>
    <title>Effect of Fluconazole on the Levels of ASCA After Surgical Resection for Crohn's Disease.</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease Aggravated</condition_summary>
    <intervention_summary>Drug: Fluconazole; Other: Placebo</intervention_summary>
    <last_changed>December 14, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>461</order>
    <score>0.88647</score>
    <nct_id>NCT03046056</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03046056</url>
    <title>Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Small Bowel Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Filgotinib; Drug: Placebo to match filgotinib</intervention_summary>
    <last_changed>July 24, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>462</order>
    <score>0.886</score>
    <nct_id>NCT01318993</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01318993</url>
    <title>Open-Label Extension Study of GSK1605786A</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: GSK1605786A</intervention_summary>
    <last_changed>March 13, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>463</order>
    <score>0.88539</score>
    <nct_id>NCT00655733</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00655733</url>
    <title>Phase II Study of HMPL-004 in Subjects With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: HMPL004; Drug: Placebo</intervention_summary>
    <last_changed>November 4, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>464</order>
    <score>0.88442</score>
    <nct_id>NCT02619552</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02619552</url>
    <title>Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; IBD</condition_summary>
    <intervention_summary>Drug: Anti-TNF; Drug: Anti-TNF; Drug: Steroids</intervention_summary>
    <last_changed>November 30, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>465</order>
    <score>0.88314</score>
    <nct_id>NCT00609973</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00609973</url>
    <title>Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Ciprofloxacin; Drug: Placebo</intervention_summary>
    <last_changed>March 21, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>466</order>
    <score>0.88274</score>
    <nct_id>NCT02341248</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02341248</url>
    <title>Bacteria &amp; Inflammation in the Gut (BIG) Study</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Other: Exclusive Enteral Nutrition (EEN)</intervention_summary>
    <last_changed>January 14, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>467</order>
    <score>0.88256</score>
    <nct_id>NCT01024647</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01024647</url>
    <title>Optimizing Cimzia in Crohn's Patients</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: certolizumab pegol; Biological: certolizumab pegol; Biological: certolizumab pegol; Biological: certolizumab pegol</intervention_summary>
    <last_changed>November 1, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>468</order>
    <score>0.88242</score>
    <nct_id>NCT02330458</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02330458</url>
    <title>The Role of Small Bowel Ultrasound in Initiation of Infliximab in Crohn's Disease Patients</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Inflammatory Bowel Disease; Crohn's Disease</condition_summary>
    <intervention_summary>Procedure: Small bowel ultrasound</intervention_summary>
    <last_changed>July 18, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>469</order>
    <score>0.88242</score>
    <nct_id>NCT00999115</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00999115</url>
    <title>Allogenic Stem Cells Derived From Lipoaspirates for the Treatment of Recto-vaginal Fistulas Associated to Crohn`s Disease (ALOREVA)</title>
    <status open="N">Completed</status>
    <condition_summary>Rectovaginal Fistula; Crohn Disease</condition_summary>
    <intervention_summary>Drug: Expanded allogenic adipose-derived adult stem cells</intervention_summary>
    <last_changed>January 25, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>470</order>
    <score>0.88199</score>
    <nct_id>NCT02677350</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02677350</url>
    <title>AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PEri-fistula iNjEctions (GALENE)</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease; Fistulizing Crohn's Disease; Stem Cells</condition_summary>
    <intervention_summary>Drug: Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)</intervention_summary>
    <last_changed>July 20, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>471</order>
    <score>0.8814</score>
    <nct_id>NCT01144962</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01144962</url>
    <title>Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Fistula</condition_summary>
    <intervention_summary>Procedure: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.; Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.</intervention_summary>
    <last_changed>December 29, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>472</order>
    <score>0.88131</score>
    <nct_id>NCT02403232</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02403232</url>
    <title>Autologous Adipose-derived Stem Cells (ASCs) for the Treatment of Perianal Fistula in Crohn Disease: A Pilot Study</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Perianal Fistula; Crohn Disease</condition_summary>
    <intervention_summary>Procedure: ASCs injection; Device: ASCs injection; Device: Closure of fistula tract.</intervention_summary>
    <last_changed>March 31, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>473</order>
    <score>0.88086</score>
    <nct_id>NCT00769236</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00769236</url>
    <title>Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Blood sampling and biopsy; Other: Biopsy and blood sampling; Other: Biopsy and blood sampling</intervention_summary>
    <last_changed>August 27, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>474</order>
    <score>0.8799</score>
    <nct_id>NCT01275508</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01275508</url>
    <title>Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: FITC-Adalimumab</intervention_summary>
    <last_changed>September 13, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>475</order>
    <score>0.87902</score>
    <nct_id>NCT02201693</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02201693</url>
    <title>Cyclic Exclusive Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Dietary Supplement: MODULEN IBD; Dietary Supplement: MODULEN IBD</intervention_summary>
    <last_changed>August 25, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>476</order>
    <score>0.87872</score>
    <nct_id>NCT03107793</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03107793</url>
    <title>Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Ustekinumab</intervention_summary>
    <last_changed>July 26, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>477</order>
    <score>0.87821</score>
    <nct_id>NCT02392286</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02392286</url>
    <title>Corticosteroid Dosage for Crohn's Disease Flare</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Inflammatory Bowel Disease</condition_summary>
    <intervention_summary>Drug: Corticosteroid</intervention_summary>
    <last_changed>July 11, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>478</order>
    <score>0.87733</score>
    <nct_id>NCT02620007</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02620007</url>
    <title>Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease; Adherent-invasive E. Coli</condition_summary>
    <intervention_summary>Drug: Ciprofloxacin; Drug: Rifaximin; Drug: Ciprofloxacin Placebo; Drug: Rifaximin Placebo</intervention_summary>
    <last_changed>June 23, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>479</order>
    <score>0.87683</score>
    <nct_id>NCT01235325</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01235325</url>
    <title>The Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Supplementation; Bone Health; Crohn's Disease</condition_summary>
    <intervention_summary>Dietary Supplement: phylloquinone (vitamin K1); Dietary Supplement: placebo</intervention_summary>
    <last_changed>November 5, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>480</order>
    <score>0.87654</score>
    <nct_id>NCT02130362</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02130362</url>
    <title>A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>April 7, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>481</order>
    <score>0.87609</score>
    <nct_id>NCT01433432</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01433432</url>
    <title>Open Label Extension Study to Protocol C2/13/DR-6MP-02</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: 80 mg DR-6MP</intervention_summary>
    <last_changed>March 5, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>482</order>
    <score>0.87477</score>
    <nct_id>NCT01577264</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01577264</url>
    <title>Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)</title>
    <status open="N">Terminated</status>
    <condition_summary>Rheumatoid Arthritis; Crohn's Disease</condition_summary>
    <last_changed>November 9, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>483</order>
    <score>0.87457</score>
    <nct_id>NCT01576471</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01576471</url>
    <title>Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Trichuris suis ova (TSO); Biological: Placebo</intervention_summary>
    <last_changed>May 30, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>484</order>
    <score>0.87261</score>
    <nct_id>NCT02782663</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02782663</url>
    <title>A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT-494 in Subjects With Crohn's Disease</title>
    <status open="N">Enrolling by invitation</status>
    <condition_summary>Crohn's Disease (CD)</condition_summary>
    <intervention_summary>Drug: ABT-494</intervention_summary>
    <last_changed>May 1, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>485</order>
    <score>0.87241</score>
    <nct_id>NCT02641392</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02641392</url>
    <title>A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: GED-0301; Other: Placebo</intervention_summary>
    <last_changed>July 25, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>486</order>
    <score>0.87224</score>
    <nct_id>NCT01180452</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01180452</url>
    <title>Endoscopic Detection of Dysplasia in Crohn 's Disease Patient</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease Located in Jejunum or Ileum</condition_summary>
    <intervention_summary>Procedure: enteroscopy</intervention_summary>
    <last_changed>June 21, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>487</order>
    <score>0.87195</score>
    <nct_id>NCT01728870</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01728870</url>
    <title>Partial Enteral Nutrition With a Unique Diet vs. Exclusive Enteral Nutrition for the Treatment of Pediatric Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Unique Diet+Partial Enteral Nutrition; Other: Exclusive Enteral Nutrition (Modulen)</intervention_summary>
    <last_changed>March 1, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>488</order>
    <score>0.87141</score>
    <nct_id>NCT01802593</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01802593</url>
    <title>Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: AZATHIOPRINE or METHOTREXATE; Drug: AZATHIOPRINE or METHOTREXATE</intervention_summary>
    <last_changed>December 21, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>489</order>
    <score>0.87131</score>
    <nct_id>NCT01393899</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01393899</url>
    <title>The Safety And Efficacy Of Maintenance Therapy With CP-690,550</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Placebo; Drug: CP-690,550; Drug: CP-690,550</intervention_summary>
    <last_changed>November 10, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>490</order>
    <score>0.87108</score>
    <nct_id>NCT03072836</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03072836</url>
    <title>Study of Gut Microbiota in Crohn's Disease Patients Suffering From Spondylarthritis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease; Spondyloarthritis</condition_summary>
    <intervention_summary>Other: analysing microbiota</intervention_summary>
    <last_changed>April 11, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>491</order>
    <score>0.87057</score>
    <nct_id>NCT02859675</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02859675</url>
    <title>Olfactogustatory Perception, Eating Behaviour and Inflammation in Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease; Olfactogustatory Perception</condition_summary>
    <intervention_summary>Other: triangular test</intervention_summary>
    <last_changed>August 4, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>492</order>
    <score>0.87048</score>
    <nct_id>NCT02559713</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02559713</url>
    <title>Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Colitis, Ulcerative; Crohn Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab</intervention_summary>
    <last_changed>June 5, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>493</order>
    <score>0.87031</score>
    <nct_id>NCT03155945</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03155945</url>
    <title>Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Abdominal Pain</condition_summary>
    <intervention_summary>Drug: APD371</intervention_summary>
    <last_changed>May 23, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>494</order>
    <score>0.86957</score>
    <nct_id>NCT01349920</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01349920</url>
    <title>Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Infliximab</intervention_summary>
    <last_changed>August 4, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>495</order>
    <score>0.86945</score>
    <nct_id>NCT00305409</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00305409</url>
    <title>Synbiotic Treatment in Crohn's Disease Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Synbiotic (Synergy I / B.longum)</intervention_summary>
    <last_changed>February 10, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>496</order>
    <score>0.86922</score>
    <nct_id>NCT02281916</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02281916</url>
    <title>Safety Study of P28GST Treatment in Crohn's Disease Patients</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Ileocolitis</condition_summary>
    <intervention_summary>Drug: P28GST</intervention_summary>
    <last_changed>June 6, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>497</order>
    <score>0.86728</score>
    <nct_id>NCT02327221</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02327221</url>
    <title>Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Ovasave; Drug: Placebo</intervention_summary>
    <last_changed>April 24, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>498</order>
    <score>0.86699</score>
    <nct_id>NCT02926300</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02926300</url>
    <title>Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)</title>
    <status open="N">Enrolling by invitation</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: stem cells</intervention_summary>
    <last_changed>October 5, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>499</order>
    <score>0.86657</score>
    <nct_id>NCT00552344</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00552344</url>
    <title>A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Biological: Cimzia</intervention_summary>
    <last_changed>January 29, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>500</order>
    <score>0.86635</score>
    <nct_id>NCT00586352</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00586352</url>
    <title>Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Ulcerative Colitis; Protein Metabolism</condition_summary>
    <intervention_summary>Other: stable isotope infusions</intervention_summary>
    <last_changed>July 29, 2016</last_changed>
  </clinical_study>
</search_results>
